TNF Pharmaceuticals (TNFA) had the best quarter in 2017 by a US stock in Q4 2017, returning 18,825,265.9%.

ASSET	QUARTER	% RETURN
TNF Pharmaceuticals (TNFA)	Q4 2017	18,825,265.85%
GT Biopharma (GTBP)	Q1 2017	1,689,552.17%
AquaBounty Technologies (AQB)	Q1 2017	153,788.89%
Ocean Power Technologies (OPTT)	Q1 2017	1,383.22%
MDxHealth SA ADR (MDXH)	Q4 2017	760%
NioCorp Developments Ltd Common Stock (NB)	Q3 2017	616.67%
Pulmatrix (PULM)	Q1 2017	523.21%
Duos Technologies (DUOT)	Q1 2017	499.63%
Riot Blockchain (RIOT)	Q4 2017	490.84%
PetVivo (PETV)	Q3 2017	475.07%
Freedom (FRHC)	Q3 2017	471.43%
Castellum (CTM)	Q1 2017	431.58%
GrabAGun Digital (PEW)	Q2 2017	421.32%
Clean Energy Technologies, Inc Common Stock (CETY)	Q2 2017	378.26%
Avalo Therapeutics (AVTX)	Q4 2017	280.95%
Veritone (VERI)	Q3 2017	279.38%
IZEA (IZEA)	Q3 2017	273.68%
Cronos (CRON)	Q4 2017	270%
Nutex Health (NUTX)	Q3 2017	266.67%
Capricor Therapeutics (CAPR)	Q3 2017	265.06%
Xunlei Ltd Adr (XNET)	Q4 2017	262.12%
VerifyMe (VRME)	Q4 2017	254.8%
Siebert Financial (SIEB)	Q4 2017	254.55%
Lexaria Bioscience (LEXX)	Q4 2017	249.9%
Opus Genetics (IRD)	Q1 2017	244.59%